Letter to the Editor | Published:

Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): A comparison with NPMc+ AML

  • A Corrigendum to this article was published on 09 March 2006

Nucleophosmin (NPM) is an ubiquitously expressed multifunctional protein.1 Although NPM is known to shuttle back and forth between the nucleus and the cytoplasm,2 only a minimum amount of the protein is present at any time in the cytoplasm; this explains why with immunohistochemistry NPM is only detectable at the nucleolar level.3 We previously showed that NPM is aberrantly expressed in the cytoplasm of anaplastic large cell lymphoma cells carrying t(2;5), due to the presence of the NPM-ALK fusion protein.3 Ectopic NPM expression parallels that of ALK protein and serves as a highly specific diagnostic test on routine biopsies.3

The t(3;5)(q25;q35) is a rare chromosomal translocation which is detected in myelodysplastic syndromes and acute myeloid leukaemia (AML),4 more frequently of FAB-M6 type. Similarly to the t(2;5) in lymphomas, it generates a chimeric gene named NPM-myelodysplasia/myeloid leukaemia factor 1 (NPM-MLF1)5 which encodes for a fusion protein containing the N-terminal portion of NPM (amino acids 1–175) linked to almost the entire MLF1 protein as only the initial 16 amino acids at the N-terminus are excluded.

We used specific antibodies against NPM3 and a newly generated specific monoclonal antibody against MLF1 (Figure 1a) (Supplementary Information), an evolutionary conserved protein whose functions and expression are poorly understood,5, 6 to study the subcellular expression of wild-type NPM and MLF1, and the chimeric NPM-MLF1 proteins in four AML patients carrying the t(3;5)/NPM-MLF1 rearrangement.

Figure 1

(a) Characterization of anti-MLF1 monoclonal antibody. Single bands of approximately 40 or 56 kDa, corresponding to FLAG-MLF1 or the FLAG-NPM-MLF1 protein, were observed on Western blotting of total lysates from FLAG-MLF1-transfected COS7 cells (lane 5) or FLAG-NPM-MLF1-transfected COS7 cells (lane 6) and AML cells with t(3;5) (lane 7). The latter specimen does not express normal endogenous MLF1. MLF1 migration is slower than endogenous MLF1 (about 31–35 kDa), likely due to the FLAG tag. Identical results were obtained following immunoprecipitation with anti-MLF1 mAb, transfer to a nitrocellulose membrane and immunoblotting with the anti-MLF1 mAb (lanes 2–4). No bands were detected in lysates of parental COS7 cells serving as negative control (lane 1). (b) Aberrant expression of MLF1 and NPM N-terminus in AML with t(3;5). Leukaemic cells with t(3;5) (marrow smear) show nucleolar (top panel, right, arrowhead) or nucleolar plus cytoplasmic positivity for MLF1 (middle panels); residual haemopoietic cell are MLF1-negative (top panel, right, arrow). Lower panel, left) Bone marrow biopsy from the same patient show leukaemic cells (inset, arrowhead) with nuclear plus cytoplasmic positivity for NPM N-terminus (arrowhead); residual haemopoietic cells exhibit nuclear-restricted NPM (arrow). Bottom panel, right) Leukaemic cells express nucleus-restricted nucleolin/C23 (arrowhead). APAAP; × 1000.

In all cases, positivity for MLF1 was found predominantly in the nucleus (mainly the nucleoli) (Figure 1b, top panel, right) or in the nucleus and the cytoplasm (Figure 1b, middle panels), confirming previous report in a single pediatric patient.5 Notably, ectopic nuclear MLF1 positivity was specific of AML carrying the t(3;5), since it was not detected in normal haemopoietic cells (Figure 1b, top and middle panels) and in acute myeloid (n=90) and lymphoid (n=30) leukaemias without t(3;5) (Supplementary Information) used as control (not shown). MLF1 nuclear positivity reflects the presence of the NPM-MLF1 protein in the nucleus.5 The NPM-MLF1 fusion protein probably manages to enter the nucleus because the portion of NPM it retains (amino acids 1–175) contains one of the two NPM nuclear localization signals that target the chimera to the nucleus.5 Hetero-dimerization of NPM-MLF1 with the wild-type NPM also may contribute to import the NPM-MLF1 fusion protein to the nucleus, as occurs with NPM-ALK in lymphomas with t(2;5).3 The cytoplasmic labelling seen with the anti-MLF1 antibody is entirely due to the NPM-MLF1 protein, since the wild-type MLF1 is not expressed in leukaemic cells with t(3;5)5 (Figure 1a).

When primary leukaemic cells with t(3;5) were labelled with the antibody against the N-terminus of NPM (retained in the NPM-MLF1 fusion protein), cytoplasmic (in addition to nuclear) positivity of NPM was revealed (Figure 1b, bottom panel, left). In contrast, expression of nucleolin/C23 (the most abundant nucleolar protein beside NPM) was nucleus-restricted (Figure 1b, bottom panel, right). These findings are consistent with the presence of the NPM-MLF1 fusion protein in the cytoplasm of leukaemic cells.

However, these experiments do not provide any information whether the NPM wild-type is also present in the cytoplasm since the anti-NPM N-terminus antibodies cannot discriminate between the NPM-MLF1 and wild-type NPM proteins.3 To address this issue, we immunostained marrow paraffin sections from our cases with two antibodies against the NPM C-terminus: one generated in our laboratory3 and the other (directed against an epitope lying within the 68 amino acids at the C-terminus of NPM) obtained from Sigma-Aldrich (Milan, Italy), both recognizing wild-type NPM but not NPM-MLF1 protein. Both antibodies detected the NPM C-terminus in the cytoplasm of AML cells with t(3;5) (Figure 2, middle panels). This staining pattern clearly differed from the nucleus-restricted NPM C-terminus expression which is found in NPM-ALK positive lymphomas (Figure 2, top panels). However, it was identical to cytoplasmic NPM C-terminus expression in AML carrying a mutated NPM protein7 (Figure 2, bottom panels). These findings could indicate that the cytoplasm of AML cells with t(3;5) contains a mutated NPM protein, or a reciprocal MLF1-NPM fusion protein or even the wild-type NPM. In the two cases, we investigated (Supplementary Information), lack of mutations in the exon-12 of the NPM gene coding region precludes leukaemic cells from carrying a mutated NPM protein. It is unlikely that MLF1-NPM reciprocal protein accounts for cytoplasmic NPM positivity since MLF1-NPM transcripts are not detectable in leukaemic cells with t(3;5)5 (Figure 1a, lane 7). However, due to the lack of fresh material for Western blotting studies, we cannot exclude with certainty that our cases contained in the cytoplasm a MLF1-NPM reciprocal fusion protein.

Figure 2

Aberrant cytoplasmic distribution of NPM C-terminus in AML with t(3;5). Top panels: tumor cells of NPM-ALK positive anaplastic large cell lymphoma (left, arrow; hematoxylin–eosin; × 800) show nuclear-restricted NPM C-terminus (right; × 800). Middle panels: Bone marrow biopsy from AML with t(3;5) (left, arrow; hematoxylin–eosin; × 800). The blast cells show nuclear plus cytoplasmic positivity for NPM C-terminus (right, arrowhead) whilst residual haemopoietic cells show nuclear-restricted NPM (right, arrow) (APAAP; × 800). Bottom panels: bone marrow biopsies from two NPMc+ AML. Bottom, left: NPMc+ AML-M6 case double stained for NPM in blue (nuclear plus cytoplasmic) and glycophorin in brown (surface expression) (APAAP/immunoperoxidase; × 800). Bottom, right: NPMc+ AML-M5 showing nuclear plus cytoplasmic positivity for NPM C-terminus (APAAP; × 800).

We favour the hypothesis that leukaemic cells with the t(3;5) may express ectopic cytoplasmic wild-type NPM. To determine whether the NPM-MLF1 fusion protein caused localization of wild-type NPM in the cytoplasm, we tranfected COS cells with pMT2-NPM-MLF1 and wild-type NPM-green fluorescent protein (pEGFP) constructs7 and immunostained them with the anti-MLF1 antibody (Supplementary Information). No perturbation in the subcellular expression of wild-type NPM was observed in transfected cells (not shown). Thus, the mechanism underlying the putative cytoplasmic dislocation of wild-type NPM remains to be clarified.

Trilineage displasia has been previously described in AML with t(3;5).4 To investigate whether the NPM-MLF1 fusion protein was present in different haemopoietic cell lineages, we immunostained two t(3;5)-AMLs with FAB-M6 morphology (Figure 3a). The nuclear plus cytoplasmic MLF1 staining which is typical of AML with t(3;5) was observed both in myeloid blasts and erythroid precursors (Figure 3b). Double immunoenzymatic staining for MLF1 and glycophorin confirmed this finding (Figure 3c). Both erythoid and myeloid populations also showed aberrant cytoplasmic expression of wild-type NPM (not shown). Among erythoid precursors, proerythroblasts were the cells showing the strongest aberrant expression of MLF1 and NPM. Both erythroid and myeloid populations were CD34-negative (not shown). Our immunohistochemical findings suggest that pathogenesis of AML with t(3;5) may involve at least a committed myeloid stem cell. Interestingly, HLS7, the murine gene counterpart to human MLF1, influences erythroid/myeloid lineage switching and development of normal haemopoietic cells.8

Figure 3

Myeloid and erythroid involvement in AML with t(3;5). (a) NPMc+ AML of FAB-M6 showing immature erythroid precursors (arrow) and scattered myeloid blasts (arrowheads) (bone marrow biopsy; Giemsa staining; × 800); (b) Both immature erythroid precursors (arrow) and clusters of myeloid blasts (arrowhead) show cytoplasmic and nuclear MLF1 staining. Unlabelled normal haemopoietic cells are also present; (c) Immature erythroid precursors coexpress MLF1 in the nucleus (brown) and glycophorin on the cell surface (blue) (arrow); myeloid blasts are glycophorin-negative/MLF1-positive (arrowhead); red blood cells are only labelled in blue.

Aberrant cytoplasmic expression of NPM and involvement of several haemopoietic cell lineages are also distinctive features of NPMc+ AML which is associated with normal karyotype.7 Despite these similarities, AML with t(3;5) and NPMc+ AML have several different features. Sequencing of NPM in leukaemic cells with t(3;5) (Supplementary Information) did not show mutations at exon-12 of NPM (or in any other part of its coding sequence). Clinically, NPMc+ AML accounts for about one-third of adult AML with the highest peak in the fifth decade7 and is usually associated with a de novo origin and favourable prognosis.9 In contrast, AML bearing t(3;5) (0.25% of all adult AML, aged 15–60 years, in the ongoing GIMEMA LAM99P/AML12 EORT trial), mainly occurs in young adults as a rapidly evolving myelodysplastic syndrome or as a de novo AML with dysplasia; it is usually associated with a poor prognosis.4 In fact, three of the four patients in our series died of their disease. The other, has been in complete clinical remission for more than three years after HLA-identical allogeneic peripheral blood stem cell transplantation.

The exact mechanism(s) through which the NPM-MLF1 protein induces malignant transformation remain unknown. Since MLF1 is not usually expressed in normal haemopoietic tissues,5, 6 NPM-MLF1 is hypothesized to contribute, at least in part, to the genesis of myelodysplasia/AML by promoting ectopic expression of MLF1 in haemopoietic cells.5, 6 Interestingly, MLF1 prevents erythroleukaemic cells from undergoing biological and morphological maturation in response to erythropoietin,10 possibly through interaction with the recently identified MLF1IP protein.11 This may also explain why AML with t(3;5) is most frequently of the FAB-M6 type. Besides, the oncogenic potential of NPM-MLF1, NPM haploinsufficiency caused by only one allele coding for wild-type NPM could play a role in leukaemogenesis. Notably, in a knockout mouse model,1 NPM is a key regulator of haematopoiesis (especially erythropoiesis). Moreover, NPM+/- heterozygous mice develop a haematological disorder with features resembling human myelodysplastic syndromes.1

In conclusion, antibodies against MLF1 and NPM are valuable tools for the biological study of AML with t(3;5). Moreover, the immunohistochemical test is rapid and inexpensive and could serve as a diagnostic surrogate for molecular studies, especially in less privileged countries.


  1. 1

    Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005; 437: 147–153.

  2. 2

    Borer RA, Lehner CF, Eppenberger HM, Nigg EA . Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989; 56: 379–390.

  3. 3

    Falini B, Mason DY . Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood 2002; 99: 409–426.

  4. 4

    Raimondi SC, Dube ID, Valentine MB, Mirro Jr J, Watt HJ, Larson RA et al. Clinicopathologic manifestations and breakpoints of the t(3;5) in patients with acute nonlymphocytic leukemia. Leukemia 1989; 3: 42–47.

  5. 5

    Yoneda-Kato N, Look AT, Kirstein MN, Valentine MB, Raimondi SC, Cohen KJ et al. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 1996; 12: 265–275.

  6. 6

    Hitzler JK, Witte DP, Jenkins NA, Copeland NG, Gilbert DJ, Naeve CW et al. cDNA cloning, expression pattern, and chromosomal localization of Mlf1, murine homologue of a gene involved in myelodysplasia and acute myeloid leukemia. Am J Pathol 1999; 155: 53–59.

  7. 7

    Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254–266.

  8. 8

    Williams JH, Daly LN, Ingley E, Beaumont JG, Tilbrook PA, Lalonde JP et al. HLS7, a hemopoietic lineage switch gene homologous to the leukemia- inducing gene MLF1. EMBO J 1999; 18: 5559–5566.

  9. 9

    Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF et al. Nucleophosmin gene mutations are predictors of favourable prognosis in acute myelogenous leukemia with a normal kayotype. Blood, published online August 2 2005.

  10. 10

    Winteringham LN, Kobelke S, Williams JH, Ingley E, Klinken SP . Myeloid Leukemia Factor 1 inhibits erythropoietin-induced differentiation, cell cycle exit and p27Kip1 accumulation. Oncogene 2004; 23: 5105–5109.

  11. 11

    Hanissian SH, Akbar U, Teng B, Janjetovic Z, Hoffmann A, Hitzler JK et al. cDNA cloning and characterization of a novel gene encoding the MLF1-interacting protein MLF1IP. Oncogene 2004; 23: 3700–3707.

Download references


This work was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC) and MURST. Supported in part by NCI Grant CA 76301 and CA 69179 (SWM), NCI Cancer Center CORE grant CA 21765 and by the American Lebanese Syrian Associated Charities (ALSAC), S. Jude Children's Research Hospital. We thank Dr Xiaoli Cui for the expert technical assistance.

Author information

Correspondence to B Falini.

Additional information

Supplementary Information accompanies the paper on Leukemia website (http://www.nature.com/leu)

Supplementary information

Supplementary Information (DOC 42 kb)

Rights and permissions

Reprints and Permissions

About this article

Further reading